Literature DB >> 22835455

TGF-β signaling via TAK1 pathway: role in kidney fibrosis.

Mary E Choi1, Yan Ding, Sung Il Kim.   

Abstract

In progressive kidney diseases, fibrosis represents the common pathway to end-stage kidney failure. Transforming growth factor-β1 (TGF-β1) is a pleiotropic cytokine that has been established as a central mediator of kidney fibrosis. Emerging evidence shows a complex scheme of signaling networks that enable multifunctionality of TGF-β1 actions. Specific targeting of the TGF-β signaling pathway is seemingly critical and an attractive molecular therapeutic strategy. TGF-β1 signals through the interaction of type I and type II receptors to activate distinct intracellular pathways involving the Smad and the non-Smad. The Smad signaling axis is known as the canonical pathway induced by TGF-β1. Importantly, recent investigations have shown that TGF-β1 also induces various non-Smad signaling pathways. In this review, we focus on current insights into the mechanism and function of the Smad-independent signaling pathway via TGF-β-activated kinase 1 and its role in mediating the profibrotic effects of TGF-β1.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22835455      PMCID: PMC3407377          DOI: 10.1016/j.semnephrol.2012.04.003

Source DB:  PubMed          Journal:  Semin Nephrol        ISSN: 0270-9295            Impact factor:   5.299


  103 in total

1.  Regulation of the TAK1 signaling pathway by protein phosphatase 2C.

Authors:  M Hanada; J Ninomiya-Tsuji; K Komaki ; M Ohnishi; K Katsura; R Kanamaru; K Matsumoto; S Tamura
Journal:  J Biol Chem       Date:  2000-12-04       Impact factor: 5.157

Review 2.  It's a Smad world: regulation of TGF-beta signaling in the kidney.

Authors:  H William Schnaper; Tomoko Hayashida; Anne-Christine Poncelet
Journal:  J Am Soc Nephrol       Date:  2002-04       Impact factor: 10.121

3.  p38 MAPK phosphorylation and NF-kappa B activation in human crescentic glomerulonephritis.

Authors:  Norihiko Sakai; Takashi Wada; Kengo Furuichi; Yasunori Iwata; Keiichi Yoshimoto; Kiyoki Kitagawa; Satoshi Kokubo; Motoo Kobayashi; Shin-ichi Takeda; Hiroshi Kida; Ken-ichi Kobayashi; Naofumi Mukaida; Kouji Matsushima; Hitoshi Yokoyama
Journal:  Nephrol Dial Transplant       Date:  2002-06       Impact factor: 5.992

Review 4.  How cells read TGF-beta signals.

Authors:  J Massagué
Journal:  Nat Rev Mol Cell Biol       Date:  2000-12       Impact factor: 94.444

5.  Stimulation of pro-alpha(1)(I) collagen by TGF-beta(1) in mesangial cells: role of the p38 MAPK pathway.

Authors:  B Y Chin; A Mohsenin; S X Li; A M Choi; M E Choi
Journal:  Am J Physiol Renal Physiol       Date:  2001-03

6.  Transforming growth factor-beta-induced mobilization of actin cytoskeleton requires signaling by small GTPases Cdc42 and RhoA.

Authors:  Sofia Edlund; Maréne Landström; Carl-Henrik Heldin; Pontus Aspenström
Journal:  Mol Biol Cell       Date:  2002-03       Impact factor: 4.138

7.  Transforming growth factor-beta1 induces collagen synthesis and accumulation via p38 mitogen-activated protein kinase (MAPK) pathway in cultured L(6)E(9) myoblasts.

Authors:  A Rodríguez-Barbero; J Obreo; L Yuste; J C Montero; A Rodríguez-Peña; A Pandiella; C Bernabéu; J M López-Novoa
Journal:  FEBS Lett       Date:  2002-02-27       Impact factor: 4.124

Review 8.  TGF-beta signaling in renal disease.

Authors:  Erwin P Böttinger; Markus Bitzer
Journal:  J Am Soc Nephrol       Date:  2002-10       Impact factor: 10.121

9.  Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism.

Authors:  N A Bhowmick; M Ghiassi; A Bakin; M Aakre; C A Lundquist; M E Engel; C L Arteaga; H L Moses
Journal:  Mol Biol Cell       Date:  2001-01       Impact factor: 4.138

10.  Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease.

Authors:  M M Shull; I Ormsby; A B Kier; S Pawlowski; R J Diebold; M Yin; R Allen; C Sidman; G Proetzel; D Calvin
Journal:  Nature       Date:  1992-10-22       Impact factor: 49.962

View more
  49 in total

1.  Genistein alleviates pressure overload-induced cardiac dysfunction and interstitial fibrosis in mice.

Authors:  Wei Qin; Ning Du; Longyin Zhang; Xianxian Wu; Yingying Hu; Xiaoguang Li; Nannan Shen; Yang Li; Baofeng Yang; Chaoqian Xu; Zhiwei Fang; Yanjie Lu; Yong Zhang; Zhimin Du
Journal:  Br J Pharmacol       Date:  2015-01-13       Impact factor: 8.739

2.  Reduced beta 2 glycoprotein I improves diabetic nephropathy via inhibiting TGF-β1-p38 MAPK pathway.

Authors:  Tong Wang; Si-Si Chen; Rui Chen; De-Min Yu; Pei Yu
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

Review 3.  Key roles for the small leucine-rich proteoglycans in renal and pulmonary pathophysiology.

Authors:  Madalina V Nastase; Renato V Iozzo; Liliana Schaefer
Journal:  Biochim Biophys Acta       Date:  2014-02-05

Review 4.  The Regulatory Effects of Transforming Growth Factor-β on Nerve Regeneration.

Authors:  Shiying Li; Xiaosong Gu; Sheng Yi
Journal:  Cell Transplant       Date:  2016-11-23       Impact factor: 4.064

Review 5.  The Effect of Low-Power Laser Therapy on the TGF/β Signaling Pathway in Chronic Kidney Disease: A Review.

Authors:  Behnaz Ahrabi; Maryam Bahrami; Reza Moghadasali; Mona Zamanian-Azodi; Maryam Sadat Khoramgah; Fatemeh Sadat Tabatabaei Mirakabad; Shahram Darabi; Hojjat Allah Abbaszadeh
Journal:  J Lasers Med Sci       Date:  2020-03-15

Review 6.  Transcriptional control of cardiac fibroblast plasticity.

Authors:  Janet K Lighthouse; Eric M Small
Journal:  J Mol Cell Cardiol       Date:  2015-12-22       Impact factor: 5.000

7.  HMGB1, TGF-β and NF-κB are associated with chronic allograft nephropathy.

Authors:  Shi-Qi Zhao; Zhen-Zhen Xue; Ling-Zhang Wang
Journal:  Exp Ther Med       Date:  2017-10-17       Impact factor: 2.447

Review 8.  TGF-β signaling in the kidney: profibrotic and protective effects.

Authors:  Angara Sureshbabu; Saif A Muhsin; Mary E Choi
Journal:  Am J Physiol Renal Physiol       Date:  2016-01-06

9.  Reduced beta 2 glycoprotein I improve diabetic nephropathy via inhibiting TGF-β1-p38 MAPK pathway.

Authors:  Tong Wang; Si-Si Chen; Rui Chen; De-Min Yu; Pei Yu
Journal:  Int J Clin Exp Med       Date:  2015-05-15

Review 10.  Therapeutic targets for treating fibrotic kidney diseases.

Authors:  So-Young Lee; Sung I Kim; Mary E Choi
Journal:  Transl Res       Date:  2014-08-13       Impact factor: 7.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.